People with Becker MD are invited to participate in a trial to determine whether a drug that increases nitric oxide levels can improve blood-flow regulation
|Update (Jan. 7, 2014): This trial is now closed to new participants.|
A new drug trial is now under way at Cedars-Sinai Medical Center in Los Angeles for men with Becker muscular dystrophy (BMD) who meet study criteria.
The study builds on previous research that demonstrated a muscle blood-flow abnormality in men with BMD that responds to a drug called tadalafil (Cialis). Tadalafil — also now being tested in BMD — increases blood flow to muscles via a biochemical mechanism called the nitric oxide pathway. The researchers will now test whether using a drug that increases nitric oxide levels can also improve blood flow to muscles. The drug works on a different part of the nitric oxide pathway.
About the study
The study requires two days at Cedars-Sinai. A participant can, for example, arrive on a Sunday and leave on a Tuesday. There is no cost to participate, and the study will cover all travel and lodging costs. It also will provide additional compensation of $150 per day (a total of $300 for two days).
Prospective participants must:
Prospective participants must not:
Contact Michael Nelson at Cedars-Sinai in Los Angeles at email@example.com or (310) 967-3844.
For more information
To learn more about blood flow and muscular dystrophy, see Enhancing Blood Flow to Exercising Muscles.
About Clinical Trials
A clinical trial is a test, in humans, of an experimental treatment. Although it's possible that benefit may be derived from participating in a clinical trial, it's also possible that no benefit, or even harm, may occur.